Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02450383 · ClinicalTrials.gov registry record · Phase 4

Comparison of Two Different Surgical Approaches To Increase Peri-Implant Mucosa Thickness

A Phase 4 study of Tooth Loss and Peri-implant Mucosa Defect, sponsored by University of Iowa.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target
1
Study location

NCT02450383 is a Phase 4 study of Tooth Loss and Peri-implant Mucosa Defect that has completed, run by University of Iowa. The registered enrollment target is 20 participants, below the 102-participant average among 11 other Tooth Loss trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02450383, a Phase 4 study of Tooth Loss and Peri-implant Mucosa Defect, has completed, sponsored by University of Iowa.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this non-inferiority trial is to determine the clinical efficacy of acellular dermal matrix (ADM) in the augmentation of the gum around dental implants as compared to an autologous gum graft (sCTG) obtained from the palate (roof of the mouth) in human adults. AlloDerm is regulated by the US Food and Drug Administration (FDA) as human tissue for transplantation. AlloDerm is processed and marketed in accordance with the FDA's requirements for banked human tissue (21 CFR, Part 1270 and Part 1271) and Standards for Tissue Banking of the American Association of Tissue Banks (AATB). Twenty adult subjects will be recruited who are in need of dental implant placement with simultaneous gum grafting to increase the thickness of the facial mucosa. Half of the subjects will be randomized to the ADM group and half will be randomized to the sCTG group. The surgical intervention will be performed according to the protocol and subjects will return for follow-up 2, 4, 8, and 16 weeks post-surgery for follow-up measurements of healing, gum thickness, subject perception of pain, and esthetic photographs.

Interventions

  • DRUG Acellular Dermal Matrix
  • PROCEDURE Autologous subepithelial connective tissue graft

Study Locations (1)

Iowa

  • University of Iowa College of Dentistry - Craniofacial Clinical Research Center and Department of Periodontics - Iowa City

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2015-01
Est. Completion 2016-09
Phase Phase 4

Sponsor

University of Iowa

228 total trials

What the Registry Record Tells You About NCT02450383

The ClinicalTrials.gov registry entry for NCT02450383 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 102-participant average among 11 other Tooth Loss trials with a reported enrollment target (80% lower). The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Tooth Loss appearing as the primary indexed condition, and to 2 interventions - of which Acellular Dermal Matrix is the first listed.

NCT02450383 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.

Frequently Asked Questions

What is clinical trial NCT02450383 about?

NCT02450383 is a clinical study titled "Comparison of Two Different Surgical Approaches To Increase Peri-Implant Mucosa Thickness". The purpose of this non-inferiority trial is to determine the clinical efficacy of acellular dermal matrix (ADM) in the augmentation of the gum around dental implants as compared to an autologous gum graft (sCTG) obtained from the palate (roof of the mouth) in human adults. AlloDerm is regulated by...

What is the current status of trial NCT02450383?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2015-01. Estimated completion is 2016-09.

What conditions does trial NCT02450383 study?

This clinical trial studies the following conditions: Tooth Loss, Peri-implant Mucosa Defect.

What interventions are being tested in trial NCT02450383?

The interventions under investigation include: Acellular Dermal Matrix (DRUG), Autologous subepithelial connective tissue graft (PROCEDURE).

Who is sponsoring clinical trial NCT02450383?

This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02450383 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tooth Loss

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.